Early-Outcomes
Early outcomes are summarized in Table 3. Lactate and pH values showed
no significant difference in the comparison of both groups over the
first 24 hours. ECMO duration was significantly shorter in the ECMO
group than in the ECMO+Impella® group (3.16\(\pm\)2.09 days ECMO vs.
6.4\(\pm\)2.79 days ECMO+Impella®, p=0.01). ECMO weaning was feasible in
29% of the ECMO group and 71% of the ECMO+Impella® group (p=0.02). The
rate of blood transfusions differed significantly between both groups
(26(13;38) units ECMO+Impella® vs. 10(3,25;18) units ECMO, p=0.01). The
rate of transfused fresh frozen plasma units did not differ between the
groups (ECMO+Impella® 10(2;15) and ECMO 2 (0;7.75), p=0.09). The
ECMO+Impella® group received significantly more platelet units (3(1;4)
vs ECMO group 0 (0;1), p<0.01).
Overall, in-hospital mortality was significantly lower in the
ECMO+Impella® group (29% ECMO+Impella® vs. 83% ECMO, p=0.01). The
survival for both groups is presented in the Kaplan-Meier plot (Figure
1).